Fig. 5.

Survivin depletion triggers an active p53 response in p53 proficient cells and modulates response to PARP inhibitors. a and b DNA damage response including BAX (BAX), NOXA (PMAIP1), p21(CDKN1A), PUMA (BBC3) p53 targets, was evaluated in Cal51 cells, 48 h after Survivin depletion (SiSurvivin) or not (SiCt), using either qPCR (a) or immunoblot analysis, this latter including Paclitaxel (700 nM) or Cisplatin (6 mM) treatments as positive controls (b). c Survivin depletion sensibilized cancer cells to the PARP inhibitor Olaparib. MCF7, MDAMB-231 and Cal51 cells were depleted in Survivin (SiSurvivin) or in BRCA1 (SiBRCA1), as previously described, and treated with olaparib at the indicated concentrations, for 4–6 days. Cell death assays were then performed and analyzed by flow cytometry